# Starling Oncology Inc. (STLN) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Health Care Equipment & Supplies. Price $5.93, market value $604 million.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Starling Oncology Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / sales: 1.0×**. Each dollar of revenue is priced at 1.0×.
- **Free-cash-flow yield: -0.5%** (5-yr avg -44.5%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Operating margin: -4.4%**. Operating margin is negative: the business loses money before interest and tax.
- **Net margin: -12.1%**. The company reported a net loss over the last twelve months.
- **Return on equity: 385.5%**. A 385.5% return on equity is extremely high; check whether buybacks or debt have shrunk the equity base, which flatters the ratio.
- **Return on invested capital: -42.3%**. Return on all capital, debt included, is -42.3%: close to or below the cost of capital, so growth may not create value.
- **Return on assets: -22.0%**. Each dollar of assets produces -22.0% of profit.

## Growth
- **Revenue growth (1 yr): 27.8%** (3-yr 25.8%/yr, 5-yr 21.8%/yr). Revenue grew 27.8% over the last year, against 21.8% a year compounded over five years: growth is accelerating.
- **EPS growth (1 yr): 23.9%**. Earnings per share rose 23.9%, roughly in step with revenue.

## Financial health
- **Interest coverage: -3.4×**. Operating profit covers interest only -3.4×: fragile.
- **Current ratio: 1.59** (quick 1.59). Current assets cover the next year's liabilities 1.59 times.
- **Altman Z-score: 4.51**. A Z-score of 4.51 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 4/9**. 4 of 9 checks pass: mixed.

## Dividends
- **Dividend: none**. Starling Oncology Inc. does not currently pay a dividend.

## Price and momentum
- **Total return (1 yr): 81.9%** (YTD 66.6%, 3-mo 21.8%). The shares are up 81.9% over twelve months including dividends.
- **From 52-week high: -15.9%** (155.6% above the low). Trading 16% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 49**. An RSI of 49 is neutral.
- **Beta (1 yr): 1.73** (volatility 80%). Beta of 1.73 against the S&P 500: the shares move much more than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=STLN · Page: https://foliofundamentals.com/stocks/stln

Not investment advice.